With vaccines for coronavirus disease 2019 (COVID-19) being introduced in countries across the world, policy makers are facing many practical considerations about how best to implement a vaccination programme. The supply of vaccines is insufficient for the global population, so decisions must be made as to which groups are prioritised for any vaccination and when. Furthermore, the aims of vaccination programmes will differ between countries, with some prioritising economic benefits that could stem from the relaxation of non-pharmaceutical interventions and others seeking simply to reduce the number of COVID-19 cases or deaths. This paper aims to share the experiences and lessons learned from conducting economic evaluations in Singapore and Thailand on hypothetical COVID-19 vaccines to provide a basis for other countries to develop their own contextualised economic evaluations, with particular focus on the key uncertainties, technical challenges, and characteristics that modellers should consider in partnership with key stakeholders. Which vaccines, vaccination strategies, and policy responses are most economically beneficial remains uncertain. It is therefore important for all governments to conduct their own analyses to inform local policy responses to COVID-19, including the implementation of COVID-19 vaccines in both the short and the long run. It is essential that such studies are designed, and ideally conducted, before vaccines are introduced so that policy decisions and implementation procedures are not delayed.

随着 2019 年冠状病毒病 (COVID-19) 疫苗在世界各国推出，政策制定者在如何最好地实施疫苗接种计划方面面临许多实际考虑。全球人口的疫苗供应不足​​，因此必须决定哪些人群优先接种疫苗以及何时接种。此外，各国疫苗接种计划的目标会有所不同，其中一些优先考虑经济利益，这可能源于放松非药物干预措施，而另一些则仅寻求减少 COVID-19 病例或死亡人数。本文旨在分享在新加坡和泰国对假设的 COVID-19 疫苗进行经济评估的经验和教训，为其他国家制定自己的情境化经济评估提供基础，特别关注关键的不确定性、技术挑战、建模者应与主要利益相关者合作考虑的特征。哪些疫苗、疫苗接种策略和政策应对措施最具经济效益仍然不确定。因此，所有政府都必须进行自己的分析，为当地应对 COVID-19 的政策提供信息，包括短期和长期实施 COVID-19 疫苗。必须设计并理想地进行此类研究，